Phase II clinical studies of erlotinib and gefitinib reported ORRs of 41.1%,14 54.1%,8 and 54.5%,15 respectively, in resectable EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.